GHRP-2
Growth Hormone Releasing Peptide-2
GHRP-2 is part of the growth-hormone secretagogue cluster that has become increasingly difficult for pharmacies to support.
Current status
Restricted
Growth-hormone-related interest, with current federal compounding constraints still in play.
FDA category
Category 3
Can pharmacies compound this?
No
Reclassification expected?
Yes
Could move if the broader secretagogue category is revisited.
Primary Use
Growth-hormone-related interest
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Sep 27, 2024
Current status signal recorded: FDA currently places it in Category 3 rather than active evaluation..
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when GHRP-2 status changes
State-specific notes
Texas
Office-use access is limited.